US equities
|
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by Impel Pharmaceuticals
Impel Pharmaceuticals Announces Exploration of Strategic Alternatives
October 05, 2023
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Impel Pharmaceuticals to Present New Real-World Data for Trudhesa® at the 65th Annual Scientific Meeting of the American Headache Society
June 15, 2023
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update
May 12, 2023
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Impel Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer
May 10, 2023
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023
May 05, 2023
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Impel Pharmaceuticals Presents New Data at AAN 2023 Suggesting Trudhesa® Nasal Spray is Safe to Use When Co-Administered With Commonly Prescribed Migraine Medications
April 26, 2023
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Impel Pharmaceuticals Announces Appointment of Darren Cline to the Board of Directors
April 12, 2023
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Impel Pharmaceuticals to Present Data on Trudhesa® Nasal Spray for Treatment of Acute Migraine at 2023 American Academy of Neurology Annual Meeting
April 11, 2023
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 24, 2023
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023
March 17, 2023
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in March
March 03, 2023
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Impel Pharmaceuticals Announces Strategic Repriortization, Continues Focus on Maximizing Trudhesa® Commercial Opportunity
February 22, 2023
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Impel Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Corporate Update
November 14, 2022
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Impel Pharmaceuticals to Participate in Guggenheim 4th Annual Immunology and Neurology Day
November 08, 2022
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Impel Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
November 07, 2022
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
